Opportunity for Evaluation of Pharmaceutical Products – Antituberculosis Medicines
10 February 2025
The Global Fund invites manufacturers of pharmaceutical products to submit an expression of interest to have their products evaluated by the Expert Review Panel for pharmaceutical products. This evaluation will focus particularly on antituberculosis medicines:
- Rifapentine / Isoniazid / Moxifloxacin, 300 mg / 75 mg / 100mg tablet
- Rifampicin / Isoniazid / Pyrazinamide / Ethambutol, 150 mg / 75 mg / 400 mg / 275 mg
- Pretomanid 200mg tablet
- Delamanid 50mg, tablet
Detailed information about the review process and submission requirements can be found on the Expert Review Panel page.
This is an open invitation and the submission of an expression of interest is possible at any time.
- Invitation to Manufacturers to Submit an Expression of Interest for Product Evaluation by the Global Fund Expert Review Panel for Pharmaceutical Products
download in English